文献速递呼吸衰竭与机械通气

白藜芦醇联合西罗莫司治疗淋巴管肌瘤病的安全性与疗效

Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.
PubMed 文献 · Chest · 2023-01-13
一句话结论2期开放标签试验:西罗莫司基础上加用白藜芦醇(250 mg/d递增至1,000 mg/d)安全、耐受良好,未达主要终点(VEGF-D下降≥42%),但VEGF-D显著下降且HRQOL有适度改善。

这是一项2期、剂量递增、开放标签试验,纳入25例接受稳定西罗莫司方案的淋巴管肌瘤病患者,白藜芦醇从250 mg/d开始、每8周递增至最大1,000 mg/d、共24周。主要终点联合治疗期间血清VEGF-D较西罗莫司基线下降≥42%,未达到;但研究期间血清VEGF-D水平有统计学显著下降、健康相关生活质量(HRQOL)有改善,除部分胃肠道副作用外耐受良好。作者认为该联合方案安全、耐受良好并与HRQOL适度改善相关,可能值得开展更大规模对照试验以明确白藜芦醇作为添加治疗的价值。

要点

  • 2期开放标签剂量递增试验:25例淋巴管肌瘤病患者,西罗莫司稳定方案基础上加用白藜芦醇250 mg/d起、每8周递增至最大1,000 mg/d、共24周。
  • 主要终点(联合治疗期间血清VEGF-D较西罗莫司基线下降≥42%)未达到。
  • 研究期间血清VEGF-D水平有统计学显著下降、HRQOL有改善;除部分胃肠道副作用外白藜芦醇耐受良好。
  • 入组时中位年龄51岁,FEV1中位绝对值1.72 L(占预计值64%),FVC中位绝对值2.99 L(占预计值96%),DLCO中位绝对值14.68 mL/mm Hg/min(占预计值37%)。
  • 基线中位血清VEGF-D 617 pg/mL;入组时西罗莫司中位剂量2 mg/d、中位谷浓度6.3 ng/mL。

适用人群与场景

  • 接受稳定西罗莫司方案的淋巴管肌瘤病患者,共25例,中位年龄51岁。
  • 入组时肺功能:FEV1中位绝对值1.72 L(占预计值64%),FVC中位绝对值2.99 L(占预计值96%),DLCO中位绝对值14.68 mL/mm Hg/min(占预计值37%)。

处置流程与药物剂量

  • 白藜芦醇起始250 mg/d,每8周递增,24周内至最大剂量1,000 mg/d,与稳定方案西罗莫司联用。
  • 患者入组时西罗莫司中位剂量2 mg/d、中位谷浓度6.3 ng/mL。

研究设计与关键结果

  • 研究类型:2期、剂量递增、开放标签试验,样本量25例淋巴管肌瘤病患者。
  • 干预:在稳定西罗莫司方案基础上加用白藜芦醇,250 mg/d起始、每8周递增至最大1,000 mg/d、共24周。
  • 主要终点:联合治疗期间血清VEGF-D较西罗莫司基线下降≥42%,未达到。
  • 次要终点:除部分胃肠道副作用外白藜芦醇耐受良好;研究期间血清VEGF-D水平有统计学显著下降、HRQOL有改善。
  • 纵向结局变化采用线性混合模型评估,不良事件按美国国家癌症研究所常见不良事件术语标准第4版列表。

证据类型、等级与局限

  • 证据类型:2期、剂量递增、开放标签试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,白藜芦醇在西罗莫司治疗的淋巴管肌瘤病患者中安全、耐受良好,并与HRQOL适度改善相关。
  • 作者认为,可能值得开展更大规模对照试验以明确白藜芦醇作为淋巴管肌瘤病添加治疗的价值。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A critical need exists to develop remission-inducing therapies for lymphangioleiomyomatosis.

RESEARCH QUESTION: Is the addition of resveratrol safe and more efficacious than sirolimus alone in patients with lymphangioleiomyomatosis?

STUDY DESIGN AND METHODS: We conducted a phase 2, dose-escalating, open-label trial of resveratrol in patients with lymphangioleiomyomatosis receiving a stable regimen of sirolimus. Resveratrol was started at 250 mg/d and escalated every 8 weeks to maximum dose of 1,000 mg/d over 24 weeks. The primary outcome was ≥ 42% decline in serum vascular endothelial growth factor D (VEGF-D) levels on combined therapy compared with baseline VEGF-D levels on sirolimus. Secondary objectives included an assessment of the safety profile and the effect on lung function and health-related quality of life (HRQOL). Longitudinal change in outcome measures was assessed using linear mixed models. Adverse effects were tabulated using the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.

RESULTS: Twenty-five patients with lymphangioleiomyomatosis with a median age of 51 years were enrolled. Pulmonary function parameters at study inclusion were: FEV1: median absolute, 1.72 L; 64% predicted; FVC: median absolute, 2.99 L; 96% predicted; and diffusing capacity of the lungs for carbon monoxide: median absolute, 14.68 mL/mm Hg/min; 37% predicted. The median serum VEGF-D value at baseline was 617 pg/mL. Patients entered the study with a median sirolimus dose of 2 mg/d with median trough level of 6.3 ng/mL. Despite some GI side effects, the addition of resveratrol was well tolerated. Although the primary outcome was not met, a statistically significant reduction in serum VEGF-D levels and improvement in HRQOL during the study was found.

INTERPRETATION: The addition of resveratrol was safe and well tolerated in patients with lymphangioleiomyomatosis taking sirolimus and was associated with modest improvement in HRQOL. Larger controlled trials of this combination might be warranted to assess definitively the usefulness of resveratrol as an additive therapy in lymphangioleiomyomatosis.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03253913; URL: www.

CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Gupta N, Zhang B, Zhou Y, et al. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis. Chest. 2023. PMID: 36642366. doi:10.1016/j.chest.2023.01.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。